Trials / Completed
CompletedNCT02395250
Anti-GPC3 CAR T for Treating Patients With Advanced HCC
Autologous T Cells Redirected to GPC3 for Treating Patients With Advanced HCC
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize glypican-3 (GPC3) is safe and effective for patients with relapsed or refractory hepatocellular carcinoma (HCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | anti-GPC3 CAR T |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2016-06-01
- Completion
- 2018-11-01
- First posted
- 2015-03-23
- Last updated
- 2019-08-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02395250. Inclusion in this directory is not an endorsement.